New options in the treatment of myelodysplastic syndrome

Journal of B.U.ON.

Volumn 10, Issue 1, 2005, Pages 35-42

  Grudeva Popova, Janet ^a  

^a MEDICAL UNIVERSITY OF PLOVDIV   (Bulgaria)

Author keywords

Classification systems; Myelodysplastic syndrome; Treatment

Indexed keywords

3 (4 AMINO 1,3 DIHYDRO 1,3 DIOXO 2H ISOINDOL 2 YL)GLUTARIMIDE; 5 AZA 2' DEOXYCYTIDINE; ARSENIC TRIOXIDE; AZACITIDINE; BORTEZOMIB; CYCLOSPORIN; CYTARABINE; DOXORUBICIN; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOMODULATING AGENT; LENALIDOMIDE; LYMPHOCYTE ANTIBODY; MELPHALAN; PROTEASOME INHIBITOR; RECOMBINANT ERYTHROPOIETIN; TAXANE DERIVATIVE; THALIDOMIDE; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; BIOLOGICAL THERAPY; CANCER RESISTANCE; CLINICAL TRIAL; CYTOPENIA; DISEASE CLASSIFICATION; DRUG POTENTIATION; DRUG SENSITIZATION; DRUG TOLERABILITY; EPIGENETICS; ERYTHROCYTE TRANSFUSION; GENE THERAPY; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA CELL; MALIGNANT TRANSFORMATION; MICROENVIRONMENT; MYELODYSPLASTIC SYNDROME; REVIEW; SIDE EFFECT; TERATOGENICITY;

EID: 24944475535     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Bennett JM. World Health Organization classification of the acute leukemias and myelodysplastic syndrome. Int J Hematol 2000; 72: 131-133.
2. Germing U, Gattermann N, Strupp C, Aivado M, Aul C. Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leuk Res 2000; 24: 983-992.
3. List AF. New approaches to the treatment of myelodysplasia. Oncologist 2002; 7 (Suppl 1): 39-49.
4. Bennett JM, Catovsky D, Daniel MT et al. French-American-British (FAB) co-operative group. Proposals for the classification of the MDS. B J Haematol 1982; 51: 189-199.
5. Harris NL, Jaffe ES, Diebold J et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. J Clin Oncol 1999; 17: 3835-3849.
6. Howe R, Porwit-MacDonald A, Wanat R, Tehranchi R, Hellstrom-Lindberg E. The WHO classification of MDS does make a difference. Blood 2004; 103: 3265-3270.
7. Deeg HJ. What is in a name? Refined diagnostic criteria for prognostic assessment in myelodysplastic syndrome (MDS). Leuk Res 2004; 28: 543-544.
8. Kanamaru A. Overview of FAB/WHO classification and therapeutic modalities for myelodysplastic syndromes. Rinsho Ketsueki (Japan) 2004; 45: 261-267.
9. Greenberg P, Cox C, Le Beau MM et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079-2088.
10. Hellstrom-Lindberg E, Gulbrandsen N, Lindberg G et al. A validated decision model for treating the anaemia of MDS with erythropoietin plus granulocyte colony stimulating factor. Significant effects on quality of life. Br J Haematol 2003; 120: 1037-1046.
11. Cassadevall N, Durieux P, Dubois S et al. Effects of erythropoietin (rHuEpo) plus granulocyte colony stimulating factor (rHuG-CSF) for the treatment of MDS on anemia, costs and quality of life: a randomized controlled trial. Blood 2004, epub On-line. DOI 10.1182.
12. Hasselbalch HC, Juhl BR, Hansen PB.The myelodysplastic syndrome II. New therapeutic principles, course and prognosis. Ugeskr Laeger 2002; 164: 479-482.
13. Aul C, Giagounidis A, Germing U et al. Myelodysplastic syndromes. Diagnosis and therapeutic strategies. Med Klin 2002; 97: 666-676.
14. Madkaikar M, Ghos K. Treating patients of myelodysplastic syndrome with antithymocytic globulin - should we be more selective? Blood 2003; 102: 3851-3852.
15. Steensma DP, Dispenzieri A, Moore SB et al. Antithymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndrome. Blood 2003; 101: 2156-2158.
16. Saif MW, Hopkins JL, Gore SD. Autoimmune phenomena in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. Leuk Lymphoma 2002; 43: 2083-2092.
17. Broliden PA, Dahl IM, Hast R et al. Antithymocyte globulin and cyclosporine A as combination therapy in myelodysplastic syndrome RA and RAEB. Blood 2002; 100: 98a (abstr).
18. Stadler M, Germing U, Kliche KO et al. A prospective, randomised, phase II study of horse antithymocyte globulin vs. rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes. Leukemia 2004; 18: 460-465.
19. Molldrem Jj, Leifer E, Bahceci E et al. Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes. Ann Intern Med 2002; 137: 156-163.
20. Killick SB, Mufti G, Cavenagh JD et al. A pilot study of antithymocyte globulin (ATG) in the treatment of patients with 'low-risk' myelodysplasia. Br J Haematol 2003; 120: 679-684.
21. Yazji S, Giles FJ, Tsimberidou AM et al. Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes. Leukemia 2003; 17: 2101-2106.
22. Shimamoto T, Ohyashiki K. Immunosuppressive treatments for myelodysplastic syndromes. Leuk Lymphoma 2003; 44: 593-604.
23. Saunthararajah Y, Nakamura R, Wesley R, Wang QJ, Barrett AJ. A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome. Blood(prepublished on June 26, 2003 as DOI 10.1182/blood-2002-11-3325).
24. Lenz W. Thalidomide and congenital abnormalities. Lancet 1962; 1: 45.
25. Kenyon BM, Browne F, D'Amato RJ. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res 1997; 64: 971-978.
26. Turk BE, Jiang H, Liu JO. Binding of thalidomide to α1-acid glycoprotein may be involved in its inhibition of tumor necrosis factor-a production. Proc Natl Acad Sci (USA) 1996; 93: 7552-7556.
27. Bellamy W, Richter L, Frutigen Y et al. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res 1999; 59: 728-733.
28. Marriott JB, Westby M, Cookson S et al. CC-3052: a water-soluble analog of thalidomide and potent inhibitor of activation-induced TNF-a production. J Immunol 1998; 161: 4236-4243.
29. List AF, Kurtin S, Glinsmann-Gibson B et al. Efficacy and safety of CC-5013 for treatment of anemia in patients with MDS. Blood 2003; 102: 184a (abstr 641). Available at: http://www.abstract2view.com/hem/view.php?nu=HEM3LI_5520.
30. Hayashi T, Hideshima T, Akiyam M et al. Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment. Mol Cancer Ther 2002; 1: 851-860.
31. Garson F, Ellison R, Kirkhart B et al. Trisenox in patients with MDS: Preliminary results of a phase I/II study. 8th Congr Eur Hematol Assoc, Lyon, France, 2003 (abstr 0721).
32. Vey N, Dreyfus F, Guerci A et al. Trisenox in patients with MDS: Preliminary results of a phase I/II study. 9th Congr Eur Hematol Assoc, Geneva, Switzerland, 2004 (abstr467).
33. Raza A, Buonamici S, Reddy P et al. MDS patients with high evi-1 expression respond well to a combination of arsenic trioxide and thalidomide. 7th Intern Symp on MDS, Paris, France, 2003 (abstr 1083).
34. Karpf AR, Jones DA. Reactivating the expression of methylation silenced genes in human cancer. Oncogene 2002; 21: 5496-5503.
35. Gryn J, Zeigler ZR, Shadduck RK et al.Treatment of myelodysplastic syndromes with 5-azacytidine.Leuk Res 2002; 26: 893-897.
36. Kantarjian HM. Treatment of myelodysplastic syndrome: questions raised by the azacytidine experience. J Clin Oncol 2002; 20: 2415-2416.
37. Kornblith AB, Herndon JE, Silverman LR et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol 2002; 20: 2441-2452.
38. Silverman LR, Demakos EP, Peterson BL et al.Randomized controlled trial of azacytidine in patients with myelodysplastic syndrome: a study of the Cancer and Leukemia Group B.J Clin Oncol 2002; 20: 2429-2437.
39. Jones PA, Kantarjian HM. Decitabine in the treatment of MDS: current developments and future directions. Clin Adv Hem Oncol 2003; 3-7.
40. Wijermans R, Lubbert M, Verhoef G. Low dose decitabine for elderly high risk MDS patients: who will respond? Am Soc Hematol, November 2003. Available at: http://www.abstracts-on-line.com/abstracts/hemphiladeiphia02/ search/results.asp?Num=0%2e4302287. Accessed November 18.2003.
41. Kantarjian HM, O'Brien S, Cortes J et al. Results of decitabine therapy in 130 patients with chronic myelogenous leukemia. Cancer 2003; 98: 522-528.
42. Dunleavy K, Janik J, Grant N et al. Phase I/II study of bortezomib combined with dose adjusted-EPOCH chemotherapy in relapsed or refractory diffuse large B-cell lymphomas. 45th Ann Meet Am Soc Hematol, San Diego CA, USA, 2003 (abstr 2349).
43. Assouline S, Belch A, Sehn L et al. A phase II study of bortezomib in patients with mantle cell lymphoma. 45th Ann Meet Am Soc Hematol, San Diego CA, USA, 2003 (abstr 3358).
44. Cortes J, Giles F, O'Brien S et al. Phase II study of bortezomib (velcade, formerly PS-341) for patients with imatinib-refractory chronic myeloid leukemia (CML) in chronic (CP) or accelerated phase (AP). 45th Ann Meet Am Soc Hematol, San Diego CA, USA, 2003 (abstr 4971).
45. Shetty V, Verspoor F, Nguyen H et al. Effect of proteasome inhibition by bortezomib on tumor necrosis factor alpha (TNF-a) and apoptosis in patients with myelodysplastic syndromes (MDS). 45th Ann Meet Am Soc Hematol, San Diego CA, USA, 2003 (abstr 1534).
46. Mitsiades C, Mitsiades N, McMullan C et al. The proteasome inhibitor bortezomib (PS-341) is active against Waldenstroms macroglobulinemia (WM). 45th Ann Meet Am Soc Hematol, San Diego CA, USA, 2003 (abstr 631).
47. Richardson PG, Schlossman RL, Weller E et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002; 100: 3063-3067.